来自MSN19 小时
ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer
The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...